Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Norland Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Firm is able to market its entire line of bone densitometers with a fracture risk feature following FDA clearance to include the feature on its Eclipse and XR-36 DXA central bone densitometers and its SCT2000 peripheral bone densitometer. Clearance of the technology for use on the three systems is the latest in a series received by the company; in February the firm's pDEXA peripheral forearm bone densitometer became the first densitometer to gain FDA clearance for use in predicting fracture risk, and in May Norland gained the same clearance for its Apollo DXA peripheral heel bone system...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts